Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review.
Ontology highlight
ABSTRACT: Preclinical and early clinical evidence suggest that radical radiotherapy of oligometastatic disease in non-small cell lung cancer (NSCLC) patients can impact outcomes with relatively limited toxicity. Whilst data from phase 2 randomized trials suggesting an improved overall survival (OS) with this treatment is promising, it has also illustrated the heterogeneity in this patient population and treatment. Oligometastatic disease in itself comprises a broad spectrum of patients, in terms of tumor load and location, stage of the disease and treatment history. This real-life variety in patient characteristics is often reflected in studies to a certain extent, hinting to the fact that all might benefit from radical radiotherapy to limited metastatic disease, yet leaving the question unanswered
SUBMITTER: Sundahl N
PROVIDER: S-EPMC8350107 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA